# Eva Harris

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 225 papers | 13,882 citations | 66 h-index | 113 g-index |
| 247 ext. papers | 16,881 ext. citations | 9.6 avg, IF | 6.62 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 225 | Dengue. *Lancet, The*, **2015**, 385, 453-65 | 40 | 691 |
| 224 | Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. *Science*, **2016**, 353, 823-6 | 33.3 | 528 |
| 223 | Antibody-dependent enhancement of severe dengue disease in humans. *Science*, **2017**, 358, 929-932 | 33.3 | 517 |
| 222 | The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. *Cell Host and Microbe*, **2010**, 8, 271-83 | 23.4 | 434 |
| 221 | Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission. *Cell Host and Microbe*, **2016**, 20, 155-66 | 23.4 | 316 |
| 220 | Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. *PLoS Pathogens*, **2010**, 6, e1000790 | 7.6 | 314 |
| 219 | Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. *Science Translational Medicine*, **2015**, 7, 304ra141 | 17.5 | 289 |
| 218 | Murine model for dengue virus-induced lethal disease with increased vascular permeability. *Journal of Virology*, **2006**, 80, 10208-17 | 6.6 | 280 |
| 217 | Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. *Science*, **2015**, 350, 217-21 | 33.3 | 253 |
| 216 | Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. *Journal of Virology*, **2004**, 78, 2701-10 | 6.6 | 252 |
| 215 | Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. *Science Translational Medicine*, **2011**, 3, 114ra128 | 17.5 | 208 |
| 214 | Infection of human cells by dengue virus is modulated by different cell types and viral strains. *Journal of Virology*, **2000**, 74, 7814-23 | 6.6 | 204 |
| 213 | Convergent antibody signatures in human dengue. *Cell Host and Microbe*, **2013**, 13, 691-700 | 23.4 | 202 |
| 212 | DIFFERENCES IN DENGUE SEVERITY IN INFANTS, CHILDREN, AND ADULTS IN A 3-YEAR HOSPITAL-BASED STUDY IN NICARAGUA. *American Journal of Tropical Medicine and Hygiene*, **2005**, 73, 1063-1070 | 3.2 | 195 |
| 211 | Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. *Clinical Infectious Diseases*, **2016**, 63, 1584-1590 | 11.6 | 179 |
| 210 | Typing of dengue viruses in clinical specimens and mosquitoes by single-tube multiplex reverse transcriptase PCR. *Journal of Clinical Microbiology*, **1998**, 36, 2634-9 | 9.7 | 177 |
| 209 | Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. *Journal of Virology*, **2010**, 84, 9227-39 | 6.6 | 170 |

| | | | |
|---|---|---|---|
| 208 | DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. *Science*, **2015**, 349, 88-91 | 33.3 | 167 |
| 207 | SEROTYPE-SPECIFIC DIFFERENCES IN CLINICAL MANIFESTATIONS OF DENGUE. *American Journal of Tropical Medicine and Hygiene*, **2006**, 74, 449-456 | 3.2 | 167 |
| 206 | Tropism of Dengue Virus in Mice and Humans Defined by Viral Nonstructural Protein 3-Specific Immunostaining. *American Journal of Tropical Medicine and Hygiene*, **2009**, 80, 416-424 | 3.2 | 167 |
| 205 | Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. *PLoS Pathogens*, **2016**, 12, e1005738 | 7.6 | 161 |
| 204 | Innate immunity to dengue virus infection and subversion of antiviral responses. *Journal of Molecular Biology*, **2014**, 426, 1148-60 | 6.5 | 149 |
| 203 | Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2357 | 4.8 | 149 |
| 202 | Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. *Science*, **2019**, 363, 607-610 | 33.3 | 147 |
| 201 | Evaluation of the traditional and revised WHO classifications of Dengue disease severity. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1397 | 4.8 | 145 |
| 200 | Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. *Virology*, **2008**, 376, 429-35 | 3.6 | 141 |
| 199 | Dengue viruses cluster antigenically but not as discrete serotypes. *Science*, **2015**, 349, 1338-43 | 33.3 | 139 |
| 198 | Precursors of human CD4 cytotoxic T lymphocytes identified by single-cell transcriptome analysis. *Science Immunology*, **2018**, 3, | 28 | 136 |
| 197 | Mouse STAT2 restricts early dengue virus replication. *Cell Host and Microbe*, **2010**, 8, 410-21 | 23.4 | 133 |
| 196 | Antibody-based assay discriminates Zika virus infection from other flaviviruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 8384-8389 | 11.5 | 129 |
| 195 | A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. *EMBO Molecular Medicine*, **2014**, 6, 358-71 | 12 | 128 |
| 194 | Obesity Increases the Duration of Influenza A Virus Shedding in Adults. *Journal of Infectious Diseases*, **2018**, 218, 1378-1382 | 7 | 127 |
| 193 | Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. *Journal of Infectious Diseases*, **2010**, 201, 5-14 | 7 | 125 |
| 192 | Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. *BMJ, The*, **2015**, 351, h3267 | 5.9 | 124 |
| 191 | CD14CD16 monocytes are the main target of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. *Nature Microbiology*, **2017**, 2, 1462-1470 | 26.6 | 119 |

| | | | |
|---|---|---|---|
| 190 | Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. *American Journal of Tropical Medicine and Hygiene*, **2005**, 73, 1063-70 | 3.2 | 119 |
| 189 | Serotype-specific differences in clinical manifestations of dengue. *American Journal of Tropical Medicine and Hygiene*, **2006**, 74, 449-56 | 3.2 | 116 |
| 188 | High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. *Tropical Medicine and International Health*, **2006**, 11, 935-42 | 2.3 | 115 |
| 187 | Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. *American Journal of Tropical Medicine and Hygiene*, **2009**, 80, 416-24 | 3.2 | 115 |
| 186 | Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. *Journal of Virology*, **2017**, 91, | 6.6 | 113 |
| 185 | Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. *PLoS Pathogens*, **2014**, 10, e1004386 | 7.6 | 113 |
| 184 | Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial Dysfunction Reflecting Disease Tropism. *Cell Reports*, **2019**, 26, 1598-1613.e8 | 10.6 | 112 |
| 183 | The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. *MBio*, **2013**, 4, e00873-13 | 7.8 | 112 |
| 182 | Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. *Frontiers in Immunology*, **2014**, 5, 280 | 8.4 | 109 |
| 181 | Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerging Infectious Diseases*, **2016**, 22, 1295-7 | 10.2 | 109 |
| 180 | Dengue: knowledge gaps, unmet needs, and research priorities. *Lancet Infectious Diseases, The*, **2017**, 17, e88-e100 | 25.5 | 104 |
| 179 | Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 728-33 | 11.5 | 103 |
| 178 | Poly(A)-binding protein binds to the non-polyadenylated 3Quntranslated region of dengue virus and modulates translation efficiency. *Journal of General Virology*, **2009**, 90, 687-692 | 4.9 | 99 |
| 177 | Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. *PLoS Medicine*, **2019**, 16, e1002726 | 11.6 | 95 |
| 176 | Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. *Journal of Infectious Diseases*, **2018**, 218, 536-545 | 7 | 95 |
| 175 | The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. *American Journal of Epidemiology*, **2009**, 170, 120-9 | 3.8 | 94 |
| 174 | Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. *Vaccine Journal*, **2003**, 10, 317-22 | | 93 |
| 173 | Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets. *Journal of Infectious Diseases*, **2015**, 212, 1743-51 | 7 | 91 |

| | | | |
|---|---|---|---|
| 172 | Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. *Journal of General Virology*, **2012**, 93, 2152-2157 | 4.9 | 90 |
| 171 | Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. *PLoS Pathogens*, **2017**, 13, e1006673 | 7.6 | 89 |
| 170 | A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. *Cell*, **2017**, 171, 229-241e15 | 36.2 | 85 |
| 169 | Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. *PLoS Pathogens*, **2014**, 10, e1004541 | 7.6 | 79 |
| 168 | Building scientific capacity in developing countries. *EMBO Reports*, **2004**, 5, 7-11 | 6.5 | 79 |
| 167 | Zika virus infection enhances future risk of severe dengue disease. *Science*, **2020**, 369, 1123-1128 | 33.3 | 78 |
| 166 | Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. *Journal of Immunology*, **2012**, 188, 404-16 | 5.3 | 76 |
| 165 | Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. *Frontiers in Immunology*, **2014**, 5, 647 | 8.4 | 75 |
| 164 | The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2462 | 4.8 | 75 |
| 163 | Rapid and specific detection of Asian- and African-lineage Zika viruses. *Science Translational Medicine*, **2017**, 9, | 17.5 | 73 |
| 162 | The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis. *Annual Review of Virology*, **2018**, 5, 227-253 | 14.6 | 71 |
| 161 | Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1568 | 4.8 | 70 |
| 160 | Single-reaction, multiplex, real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2116 | 4.8 | 66 |
| 159 | High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. *PLoS Neglected Tropical Diseases*, **2010**, 4, e633 | 4.8 | 65 |
| 158 | Economic and disease burden of dengue in Mexico. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003547 | 4.8 | 64 |
| 157 | Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2274 | 4.8 | 64 |
| 156 | Homotypic Dengue Virus Reinfections in Nicaraguan Children. *Journal of Infectious Diseases*, **2016**, 214, 986-93 | 7 | 60 |
| 155 | Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. *Cell Host and Microbe*, **2018**, 23, 855-864.e7 | 23.4 | 60 |

| | | | |
|---|---|---|---|
| 154 | Regulation of Flavivirus RNA synthesis and replication. *Current Opinion in Virology*, **2014**, 9, 74-83 | 7.5 | 59 |
| 153 | Therapeutic efficacy of antibodies lacking Fc receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. *PLoS Pathogens*, **2013**, 9, e1003157 | 7.6 | 59 |
| 152 | Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. *Nature Biotechnology*, **2019**, 37, 160-168 | 44.5 | 57 |
| 151 | Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. *PLoS ONE*, **2011**, 6, e27252 | 3.7 | 56 |
| 150 | Immune correlates of protection for dengue: State of the art and research agenda. *Vaccine*, **2017**, 35, 4659-4669 | 4.1 | 55 |
| 149 | Mosquito Saliva Increases Endothelial Permeability in the Skin, Immune Cell Migration, and Dengue Pathogenesis during Antibody-Dependent Enhancement. *PLoS Pathogens*, **2016**, 12, e1005676 | 7.6 | 54 |
| 148 | Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype. *Journal of Virology*, **2016**, 90, 4771-4779 | 6.6 | 53 |
| 147 | Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016 epidemic in Managua, Nicaragua. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 9294-9299 | 11.5 | 53 |
| 146 | Assessing the epidemiological effect of wolbachia for dengue control. *Lancet Infectious Diseases, The*, **2015**, 15, 862-6 | 25.5 | 52 |
| 145 | Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay. *MBio*, **2018**, 9, | 7.8 | 51 |
| 144 | Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. *Journal of Clinical Virology*, **2008**, 43, 287-91 | 14.5 | 51 |
| 143 | Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004524 | 4.8 | 51 |
| 142 | Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. *Journal of Clinical Microbiology*, **2018**, 56, | 9.7 | 50 |
| 141 | Global Assessment of Dengue Virus-Specific CD4 T Cell Responses in Dengue-Endemic Areas. *Frontiers in Immunology*, **2017**, 8, 1309 | 8.4 | 49 |
| 140 | Mosquito Biting Modulates Skin Response to Virus Infection. *Trends in Parasitology*, **2017**, 33, 645-657 | 6.4 | 47 |
| 139 | Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2451 | 4.8 | 46 |
| 138 | Dissecting the human serum antibody response to secondary dengue virus infections. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005554 | 4.8 | 45 |
| 137 | Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests. *Clinical Infectious Diseases*, **2017**, 65, 1829-1836 | 11.6 | 45 |

| | | | |
|---|---|---|---|
| 136 | Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1966 | 4.8 | 42 |
| 135 | Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. *Journal of Immunology*, **2017**, 198, 4025-4035 | 5.3 | 41 |
| 134 | Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004449 | 4.8 | 41 |
| 133 | Zika Virus Replicates in Proliferating Cells in Explants From First-Trimester Human Placentas, Potential Sites for Dissemination of Infection. *Journal of Infectious Diseases*, **2018**, 217, 1202-1213 | 7 | 40 |
| 132 | Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. *Molecular Systems Biology*, **2018**, 14, e7862 | 12.2 | 40 |
| 131 | Molecular biology of flaviviruses. *Novartis Foundation Symposium*, **2006**, 277, 23-39; discussion 40, 71-3, 251-3 | | 39 |
| 130 | Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. *Virus Research*, **2018**, 254, 27-33 | 6.4 | 38 |
| 129 | Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4. *Antiviral Research*, **2016**, 129, 93-98 | 10.8 | 38 |
| 128 | Molecular Biology of Flaviviruses. *Novartis Foundation Symposium*, **2008**, 23-40 | | 38 |
| 127 | Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8 T Cells. *Journal of Immunology*, **2018**, 201, 3487-3491 | 5.3 | 38 |
| 126 | Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. *Journal of Clinical Microbiology*, **2018**, 56, | 9.7 | 36 |
| 125 | Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. *Journal of Clinical Virology*, **2016**, 78, 57-61 | 14.5 | 36 |
| 124 | Characterization of Aedes aegypti (Diptera: Culcidae) Production Sites in Urban Nicaragua. *Journal of Medical Entomology*, **2007**, 44, 851-860 | 2.2 | 36 |
| 123 | Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. *Vaccine*, **2018**, 36, 3411-3417 | 4.1 | 35 |
| 122 | Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003904 | 4.8 | 35 |
| 121 | Evaluation of the diagnostic utility of the traditional and revised WHO dengue case definitions. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2385 | 4.8 | 35 |
| 120 | The decline of dengue in the Americas in 2017: discussion of multiple hypotheses. *Tropical Medicine and International Health*, **2019**, 24, 442-453 | 2.3 | 34 |
| 119 | Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. *EBioMedicine*, **2018**, 27, 61-70 | 8.8 | 33 |

| | | | |
|---|---|---|---|
| 118 | Endocytosis of flavivirus NS1 is required for NS1-mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation. *PLoS Pathogens*, **2019**, 15, e1007938 | 7.6 | 33 |
| 117 | Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. *Journal of Virology*, **2014**, 88, 13125-34 | 6.6 | 33 |
| 116 | Rearing of spp. and spp. Mosquitoes. *Bio-protocol*, **2017**, 7, | 0.9 | 30 |
| 115 | Seroprevalence of Anti-Chikungunya Virus Antibodies in Children and Adults in Managua, Nicaragua, After the First Chikungunya Epidemic, 2014-2015. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004773 | 4.8 | 30 |
| 114 | Intrahost Selection Pressures Drive Rapid Dengue Virus Microevolution in Acute Human Infections. *Cell Host and Microbe*, **2017**, 22, 400-410.e5 | 23.4 | 28 |
| 113 | Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction. *Science*, **2021**, 371, 194-200 | 33.3 | 28 |
| 112 | Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. *Journal of Virology*, **2016**, 90, 5090-5097 | 6.6 | 27 |
| 111 | Unusual dengue virus 3 epidemic in Nicaragua, 2009. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1394 | 4.8 | 27 |
| 110 | Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. *Nature Communications*, **2019**, 10, 938 | 17.4 | 27 |
| 109 | Multiplex nucleic acid amplification test for diagnosis of dengue fever, malaria, and leptospirosis. *Journal of Clinical Microbiology*, **2014**, 52, 2011-8 | 9.7 | 26 |
| 108 | Index cluster study of dengue virus infection in Nicaragua. *American Journal of Tropical Medicine and Hygiene*, **2010**, 83, 683-9 | 3.2 | 26 |
| 107 | FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12943-12951 | 11.5 | 25 |
| 106 | Infectious Chikungunya Virus in the Saliva of Mice, Monkeys and Humans. *PLoS ONE*, **2015**, 10, e0139481 | 3.7 | 25 |
| 105 | T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. *Journal of Virology*, **2020**, 94, | 6.6 | 24 |
| 104 | Mobilising communities for Aedes aegypti control: the SEPA approach. *BMC Public Health*, **2017**, 17, 403 | 4.1 | 24 |
| 103 | Camino Verde (The Green Way): evidence-based community mobilisation for dengue control in Nicaragua and Mexico: feasibility study and study protocol for a randomised controlled trial. *BMC Public Health*, **2017**, 17, 407 | 4.1 | 23 |
| 102 | Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection. *Cell Reports*, **2020**, 31, 107569 | 10.6 | 22 |
| 101 | Zika Virus Nonstructural Protein 1 Disrupts Glycosaminoglycans and Causes Permeability in Developing Human Placentas. *Journal of Infectious Diseases*, **2020**, 221, 313-324 | 7 | 22 |

| | | | |
|---|---|---|---|
| 100 | Clinical Attack Rate of Chikungunya in a Cohort of Nicaraguan Children. *American Journal of Tropical Medicine and Hygiene*, **2016**, 94, 397-9 | 3.2 | 21 |
| 99 | Improvement in Hospital Indicators after Changes in Dengue Case Management in Nicaragua. *American Journal of Tropical Medicine and Hygiene*, **2009**, 81, 287-292 | 3.2 | 21 |
| 98 | Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay. *Journal of Immunology*, **2015**, 195, 3490-6 | 5.3 | 20 |
| 97 | Differing epidemiological dynamics of Chikungunya virus in the Americas during the 2014-2015 epidemic. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006670 | 4.8 | 20 |
| 96 | Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005721 | 4.8 | 19 |
| 95 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. *Current Opinion in Virology*, **2020**, 43, 59-70 | 7.5 | 19 |
| 94 | Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection. *Journal of Virology*, **2019**, 93, | 6.6 | 19 |
| 93 | Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. *Journal of Infectious Diseases*, **2020**, 221, 1846-1854 | 7 | 18 |
| 92 | Differences in Transmission and Disease Severity Between 2 Successive Waves of Chikungunya. *Clinical Infectious Diseases*, **2018**, 67, 1760-1767 | 11.6 | 16 |
| 91 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10, | 10.2 | 16 |
| 90 | Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-Barr Syndrome. *Journal of Infectious Diseases*, **2019**, 219, 26-30 | 7 | 16 |
| 89 | Zika virus infection of first-trimester human placentas: utility of an explant model of replication to evaluate correlates of immune protection ex vivo. *Current Opinion in Virology*, **2017**, 27, 48-56 | 7.5 | 16 |
| 88 | The Nicaraguan pediatric influenza cohort study: design, methods, use of technology, and compliance. *BMC Infectious Diseases*, **2015**, 15, 504 | 4 | 16 |
| 87 | Effects of infection history on dengue virus infection and pathogenicity. *Nature Communications*, **2019**, 10, 1246 | 17.4 | 15 |
| 86 | Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate. *Journal of Infectious Diseases*, **2020**, 221, 867-877 | 7 | 15 |
| 85 | Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10762-10767 | 11.5 | 15 |
| 84 | Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses. *Journal of Immunology*, **2019**, 202, 1153-1162 | 5.3 | 14 |
| 83 | Improvement in hospital indicators after changes in dengue case management in Nicaragua. *American Journal of Tropical Medicine and Hygiene*, **2009**, 81, 287-92 | 3.2 | 14 |

| | | | |
|---|---|---|---|
| 82 | The Role of Heterotypic DENV-specific CD8T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection. *EBioMedicine*, **2017**, 20, 202-216 | 8.8 | 13 |
| 81 | Molecular Signatures of Dengue Virus-Specific IL-10/IFN-□Co-producing CD4˚T Cells and Their Association with Dengue Disease. *Cell Reports*, **2019**, 29, 4482-4495.e4 | 10.6 | 13 |
| 80 | Chikungunya Virus Sequences Across the First Epidemic in Nicaragua, 2014-2015. *American Journal of Tropical Medicine and Hygiene*, **2016**, 94, 400-3 | 3.2 | 12 |
| 79 | Internally Controlled, Multiplex Real-Time Reverse Transcription PCR for Dengue Virus and Yellow Fever Virus Detection. *American Journal of Tropical Medicine and Hygiene*, **2018**, 98, 1833-1836 | 3.2 | 12 |
| 78 | Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. *Lancet Infectious Diseases, The*, **2020**, 20, 371-380 | 25.5 | 12 |
| 77 | Genome-wide, bidirectional CRISPR screens identify mucins as critical host factors modulating SARS-CoV-2 infection | | 12 |
| 76 | Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia. *European Journal of Immunology*, **2017**, 47, 527-539 | 6.1 | 11 |
| 75 | Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue. *Journal of Infectious Diseases*, **2020**, 222, 590-600 | 7 | 11 |
| 74 | The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection. *Current Opinion in Virology*, **2018**, 29, 51-61 | 7.5 | 11 |
| 73 | Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. *MBio*, **2017**, 8, | 7.8 | 11 |
| 72 | In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection. *Antiviral Research*, **2020**, 173, 104668 | 10.8 | 11 |
| 71 | Combination of Nonstructural Protein 1-Based Enzyme-Linked Immunosorbent Assays Can Detect and Distinguish Various Dengue Virus and Zika Virus Infections. *Journal of Clinical Microbiology*, **2019**, 57, | 9.7 | 11 |
| 70 | "Where we put little fish in the water there are no mosquitoes:" a cross-sectional study on biological control of the Aedes aegypti vector in 90 coastal-region communities of Guerrero, Mexico. *BMC Public Health*, **2017**, 17, 433 | 4.1 | 10 |
| 69 | Zika virus infection in Nicaraguan households. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006518 | 4.8 | 10 |
| 68 | Development of in-house serological methods for diagnosis and surveillance of chikungunya. *Revista Panamericana De Salud Publica/Pan American Journal of Public Health*, **2017**, 41, e56 | 4.1 | 10 |
| 67 | Assessing the Incidence of Symptomatic Respiratory Syncytial Virus Illness Within a Prospective Birth Cohort in Managua, Nicaragua. *Clinical Infectious Diseases*, **2020**, 70, 2029-2035 | 11.6 | 10 |
| 66 | International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. *BMC Pregnancy and Childbirth*, **2019**, 19, 282 | 3.2 | 9 |
| 65 | Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity. *Journal of Clinical Virology*, **2015**, 69, 63-7 | 14.5 | 9 |

| | | | |
|---|---|---|---|
| 64 | The Camino Verde intervention in Nicaragua, 2004-2012. *BMC Public Health*, **2017**, 17, 406 | 4.1 | 9 |
| 63 | Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. *Journal of Infectious Diseases*, **2016**, 213, 975-84 | 7 | 9 |
| 62 | Characterization of Dengue Virus Infections Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua. *Journal of Infectious Diseases*, **2017**, 215, 1816-1823 | 7 | 9 |
| 61 | Broad and strong: the ultimate antibody to dengue virus. *Nature Immunology*, **2015**, 16, 135-7 | 19.1 | 9 |
| 60 | When communities are really in control: ethical issues surrounding community mobilisation for dengue prevention in Mexico and Nicaragua. *BMC Public Health*, **2017**, 17, 410 | 4.1 | 8 |
| 59 | Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. *Cell Host and Microbe*, **2020**, 27, 710-724.e7 | 23.4 | 7 |
| 58 | Community cost-benefit discussions that launched the Camino Verde intervention in Nicaragua. *BMC Public Health*, **2017**, 17, 396 | 4.1 | 7 |
| 57 | HLA Upregulation During Dengue Virus Infection Suppresses the Natural Killer Cell Response. *Frontiers in Cellular and Infection Microbiology*, **2019**, 9, 268 | 5.9 | 7 |
| 56 | Increased serum sialic acid is associated with morbidity and mortality in a murine model of dengue disease. *Journal of General Virology*, **2019**, 100, 1515-1522 | 4.9 | 7 |
| 55 | Rapid, point-of-care molecular diagnostics with Cas13 **2021**, | | 7 |
| 54 | Developmental outcomes in children exposed to Zika virus in utero from a Brazilian urban slum cohort study. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009162 | 4.8 | 7 |
| 53 | Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. *Vaccine*, **2017**, 35, 6202-6207 | 4.1 | 6 |
| 52 | Preparation of Mosquito Salivary Gland Extract and Intradermal Inoculation of Mice. *Bio-protocol*, **2017**, 7, | 0.9 | 6 |
| 51 | ELISPOT-Based "Multi-Color FluoroSpot" to Study Type-Specific and Cross-Reactive Responses in Memory B Cells after Dengue and Zika Virus Infections. *Methods in Molecular Biology*, **2018**, 1808, 151-163 | 1.4 | 6 |
| 50 | Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers. *Journal of Infectious Diseases*, **2018**, 218, 1911-1921 | 7 | 6 |
| 49 | Low seroprevalence rates of Zika virus in Kuala Lumpur, Malaysia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **2019**, 113, 678-684 | 2 | 6 |
| 48 | Modulation of Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons. *Journal of Virology*, **2000**, 74, 4957-4966 | 6.6 | 6 |
| 47 | Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses. *F1000Research*, **2019**, 8, 1875 | 3.6 | 6 |

| | | | |
|---|---|---|---|
| 46 | Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. *Lancet Infectious Diseases, The*, **2021**, | 25.5 | 6 |
| 45 | Monocyte-plasmablast crosstalk during dengue. *Cell Host and Microbe*, **2014**, 16, 7-9 | 23.4 | 5 |
| 44 | Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries. *EBioMedicine*, **2020**, 51, 102584 | 8.8 | 5 |
| 43 | Studying the Endothelial Glycocalyx : What Is Missing?. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 647086 | 5.4 | 5 |
| 42 | Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. *Clinical Infectious Diseases*, **2021**, | 11.6 | 5 |
| 41 | Introduction and Establishment of Aedes albopictus (Diptera: Culicidae) in Managua, Nicaragua. *Journal of Medical Entomology*, **2015**, 52, 713-8 | 2.2 | 4 |
| 40 | Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic. *PLoS ONE*, **2020**, 15, e0230692 | 3.7 | 4 |
| 39 | Beyond efficacy in water containers: Temephos and household entomological indices in six studies between 2005 and 2013 in Managua, Nicaragua. *BMC Public Health*, **2017**, 17, 434 | 4.1 | 4 |
| 38 | Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. *Scientific Reports*, **2019**, 9, 16258 | 4.9 | 4 |
| 37 | Avian anti-NS1 IgY antibodies neutralize dengue virus infection and protect against lethal dengue virus challenge. *Antiviral Research*, **2020**, 183, 104923 | 10.8 | 4 |
| 36 | Reply to G□ardin et al. *Clinical Infectious Diseases*, **2019**, 68, 172-174 | 11.6 | 4 |
| 35 | Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. *Human Immunology*, **2018**, 79, 1-2 | 2.3 | 4 |
| 34 | Yes we can! The Raffles Dialogue on Human Wellbeing and Security. *The Lancet Global Health*, **2015**, 3, e496-e500 | 13.6 | 3 |
| 33 | Dengue occurrence relations and serology: cross-sectional analysis of results from the Guerrero State, Mexico, baseline for a cluster-randomised controlled trial of community mobilisation for dengue prevention. *BMC Public Health*, **2017**, 17, 435 | 4.1 | 3 |
| 32 | Informed community mobilization for dengue prevention in households with and without a regular water supply: Secondary analysis from the Camino Verde trial in Nicaragua. *BMC Public Health*, **2017** , 17, 395 | 4.1 | 3 |
| 31 | Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. *Science Translational Medicine*, **2021**, 13, eabg9478 | 17.5 | 3 |
| 30 | Individual-level Association of Influenza Infection With Subsequent Pneumonia: A Case-control and Prospective Cohort Study. *Clinical Infectious Diseases*, **2021**, 73, e4288-e4295 | 11.6 | 3 |
| 29 | Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009641 | 4.8 | 3 |

| | | | |
|---|---|---|---|
| 28 | Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. *Journal of Infectious Diseases*, **2021**, 223, 247-257 | 7 | 3 |
| 27 | Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California. *JAMA Network Open*, **2021**, 4, e2124116 | 10.4 | 3 |
| 26 | Levels of Circulating NS1 Impact West Nile Virus Spread to the Brain. *Journal of Virology*, **2021**, 95, e00844 | 6.6 | 3 |
| 25 | ImmuneRegulation: a web-based tool for identifying human immune regulatory elements. *Nucleic Acids Research*, **2019**, 47, W142-W150 | 20.1 | 2 |
| 24 | Evaluation of ViroTrack Sero Zika IgG/IgM, a New Rapid and Quantitative Zika Serological Diagnostic Assay. *Diagnostics*, **2020**, 10, | 3.8 | 2 |
| 23 | Obesity Is Associated With Increased Susceptibility to Influenza A (H1N1pdm) but Not H3N2 Infection. *Clinical Infectious Diseases*, **2021**, 73, e4345-e4352 | 11.6 | 2 |
| 22 | SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF- signaling. **2021**, | | 2 |
| 21 | Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses. *F1000Research*, **2019**, 8, 1875 | 3.6 | 2 |
| 20 | Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118, | 11.5 | 2 |
| 19 | Pre-existing T Cell Memory against Zika Virus. *Journal of Virology*, **2021**, 95, | 6.6 | 2 |
| 18 | CyTOF Profiling of Zika and Dengue Virus-Infected Human Peripheral Blood Mononuclear Cells Identifies Phenotypic Signatures of Monotype Subsets and Upregulation of the Interferon-Inducible Protein CD169. *MSphere*, **2021**, 6, e0050521 | 5 | 2 |
| 17 | Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in Nicaragua and Mexico: A cluster randomized controlled trial. *International Journal of Infectious Diseases*, **2020**, 94, 59-67 | 10.5 | 1 |
| 16 | T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species | | 1 |
| 15 | Interferon receptor-deficient mice are susceptible to eschar-associated rickettsiosis | | 1 |
| 14 | Dengue Immunopathogenesis: A Crosstalk between Host and Viral Factors Leading to Disease: Part I - Dengue Virus Tropism, Host Innate Immune Responses, and Subversion of Antiviral Responses **2020**, | | 1 |
| 13 | Evolution and epidemiologic dynamics of dengue virus in Nicaragua during the emergence of chikungunya and Zika viruses. *Infection, Genetics and Evolution*, **2021**, 92, 104680 | 4.5 | 1 |
| 12 | Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. *Frontiers in Immunology*, **2021**, 12, 703887 | 8.4 | 1 |
| 11 | The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking Formation of the Membranous Replication Compartment. *Journal of Virology*, **2021**, 95, e0099621 | 6.6 | 1 |

| | | | |
|---|---|---|---|
| 10 | Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua.. *Nature Communications*, **2022**, 13, 1190 | 17.4 | 1 |
| 9 | Molecular Determinants of Tissue Specificity of Flavivirus Nonstructural Protein 1 Interaction with Endothelial Cells | | 1 |
| 8 | Utility of entomological indices for predicting transmission of dengue virus: secondary analysis of data from the Camino Verde trial in Mexico and Nicaragua. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008768 | 4.8 | 0 |
| 7 | Viral genome-based Zika virus transmission dynamics in a paediatric cohort during the 2016 Nicaragua epidemic. *EBioMedicine*, **2021**, 72, 103596 | 8.8 | 0 |
| 6 | Pneumonia Following Symptomatic Influenza Infection Among Nicaraguan Children Before and After Introduction of the Pneumococcal Conjugate Vaccine. *Journal of Infectious Diseases*, **2021**, 224, 643-647 | 7 | 0 |
| 5 | Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. *Journal of Virology*, **2021**, 95, e0061921 | 6.6 | 0 |
| 4 | Flavivirus NS1 Triggers Tissue-Specific Disassembly of Intercellular Junctions Leading to Barrier Dysfunction and Vascular Leak in a GSK-3Dependent Manner. *Pathogens*, **2022**, 11, 615 | 4.5 | 0 |
| 3 | Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses. *F1000Research*,8, 1875 | 3.6 | |
| 2 | Migration of Disease **2020**, 96-130 | | |
| 1 | Sulfated glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis.. *Antiviral Research*, **2022**, 105330 | 10.8 | |